Schering Corporation

Merck Sharp + Dohme Corp.

Intervet Inc.

Intervet International B.v.

Keith A Eagen

Mariappan Chelliah

Samuel Chackalamannil

Yan Xia

William J Greenlee

Martin C Clasby

Henry M Vaccaro

Brian Alexander McKittrick

Jack D Scott

Srikanth Venkatraman

Jason M Cox

Zhuyan Guo

John S Debenham

Tin-Yau Chan

Kartik M Keertikar

Clare London

Unmesh G Shah

Christopher Joseph Sinz

Yuguang Wang

Ping Lan

Hong Dong Chu

Zhongxiang Sun

Haiyan Pu

Li Wang

Xiaobang Gao

Michael A Plotkin

Liyuan Wang

Mariappan V Chelliah

Brian Mckittrick

Li Yuan Wang

Charles L Jayne

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. 

Substituted spiropiperidinyl compounds useful as GPR120 agonists

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

Heterocyclic compounds as factor IXA inhibitors

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

Cannabinoid receptor modulators

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R, R, R, Rand Rare herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

Thrombin receptor antagonists

Growing community of inventors

West Orange, NJ, United States of America

Keith A Eagen